Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Trump Says Anthropic No Longer Seen as National Security Threat 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
CAMBRIDGE, Mass., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the 34th Annual J.P. Morgan Healthcare Conference in San Francisco. Chairman of the Board of Directors Sandford D. Smith is scheduled to present on Thursday, January 14, 2016 at 8:00 a.m. PST (11:00 a.m. EST). Mr. Smith will also introduce Aegerion’s newly appointed Chief Executive Officer, Mary Szela.
The presentation will be webcast live and may be accessed for up to 30 days following the conference by visiting the “Investors” section of Aegerion’s website, www.aegerion.com.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. For more information about the company, please visit www.aegerion.com.
CONTACT: Aegerion Pharmaceuticals, Inc. Amanda Murphy Associate Director, Investor Relations 857-242-5024
